Pancreatic Cancer Research

ResearcherUniversity of VeronaNo recent work listed

Francesca Simionato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5497-2866; OpenAlex author ID A5055751658. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 10

  1. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  2. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0395↗
  3. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0270↗
  4. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  5. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Co-author DOI 10.3390/cells9020309↗
  6. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  7. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-019-03807-4↗
  8. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. Co-author DOI 10.1038/ijo.2017.285↗
  9. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
  10. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. First author DOI 10.1080/2162402x.2017.1322242↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davide Melisi · 9 shared papers, 2017–2020 · strength 0.70
  2. Valeria Merz · 6 shared papers, 2017–2020 · strength 0.47
  3. Raffaela Santoro · 5 shared papers, 2017–2020 · strength 0.42
  4. Geny Piro · 4 shared papers, 2017–2020 · strength 0.33
  5. Aldo Scarpa · 4 shared papers, 2017–2020 · strength 0.33
  6. Giuseppe Malleo · 3 shared papers, 2017–2020 · strength 0.20
  7. Claudio Bassi · 3 shared papers, 2017–2020 · strength 0.20
  8. Michèle Milella · 2 shared papers, 2020 · strength 0.17
  9. Massimiliano Tuveri · 2 shared papers, 2019–2020 · strength 0.14
  10. Alessandro Esposito · 2 shared papers, 2019–2020 · strength 0.14
  11. Mirko D’Onofrio · 2 shared papers, 2019–2020 · strength 0.14
  12. Salvatore Paiella · 2 shared papers, 2019–2020 · strength 0.14
  13. Giovanni Marchegiani · 2 shared papers, 2019–2020 · strength 0.14
  14. Roberto Salvia · 2 shared papers, 2019–2020 · strength 0.14
  15. Giampaolo Tortora · 2 shared papers, 2017–2018 · strength 0.12
  16. Carmine Carbone · 2 shared papers, 2017–2018 · strength 0.12
  17. Vanja Vaccaro · 1 shared paper, 2020 · strength 0.10
  18. Chiara Bazzichetto · 1 shared paper, 2020 · strength 0.10
  19. Vincenzo Corbo · 1 shared paper, 2020 · strength 0.10
  20. Sara Lonardi · 1 shared paper, 2020 · strength 0.10
  21. Ludovica Ciuffreda · 1 shared paper, 2020 · strength 0.10
  22. Claudio Luchini · 1 shared paper, 2020 · strength 0.10
  23. G. Deplanque · 1 shared paper, 2019 · strength 0.08
  24. Denis Pezet · 1 shared paper, 2019 · strength 0.08
  25. Karim Adnane Benhadji · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.